BioMark Announces New Patent Granted in China

Vancouver, British Columbia – (March 12, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been granted in China on February 15, 2019.   Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]

Dr. Myron Weisfedlt Joins BioMark’s Scientific Advisory Team

Vancouver, British Columbia – (November 5th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team.   Mr. Rashid Ahmed, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Dr. Myron Weisfeldt […]

BioMark Closes Final Tranche of Private Placement Offering

October 4th, 2018 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 […]

Dr. Sandeep Singhal Joins BioMaark Scientific Advisory Team

Vancouver, British Columbia – (October 2nd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team. Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise […]

BioMark Contributes in Scientific Publication

Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA.   Rashid Ahmed, President and CEO, says, “We are extremely excited […]

Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team

Vancouver, British Columbia – (September 19th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team.   Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His […]

BioMark Diagnostics – Sponsored Project Receives NSERC Engage Grant

Vancouver, British Columbia – (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of  Pharmacology and Therapeutics  at the University of Manitoba, to fabricate new nanomaterial and focus […]

BioMark’s Health Canada Submission Update

Vancouver, British Columbia – (February 21st, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities. Listed below are new accomplishments over the past 2 weeks:  BioMark’s regulatory team at St. Boniface Hospital […]

Further Progress in BIOMARK’s Clinical Trial and Regulatory Review

Vancouver, British Columbia – (January 3rd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide further progress on its clinical trial activities as previously reported on November 1st, 2017. New accomplishments over the past few weeks are listed below.  Samples from the outlier cohort have been received at […]